Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL109451 | 0.85 | CA1 (0.61) | CA12CA1CA2CA9CA14 | |
| SCHEMBL29334997 | 0.85 | MAPT (0.46) | CA12CA1CA2CA9CA14 | |
| SCHEMBL16823492 | 0.85 | CA12 (0.50) | CA12CA1CA2CA9CA14 | |
| SCHEMBL24812731 | 0.83 | GSK3B (0.55) | CA12CA1CA2CA9CA14 | |
| SCHEMBL7588248 | 0.82 | ALDH1A1 (0.55) | CA12CA1CA2CA9CA14 | |
| SCHEMBL12980480 | 0.82 | HSD17B3 (0.59) | CA12CA1CA2CA9CA14 | |
| SCHEMBL8564509 | 0.81 | ELANE (0.49) | CA12CA1CA2CA9CA14 | |
| SCHEMBL28014893 | 0.81 | ALDH1A1 (0.62) | CA12CA1CA2CA9CA14 | |
| Hydrazine SCHEMBL10771056 | 0.81 | CA12 (0.62) | CA12CA1CA2CA9CA14 | |
| SCHEMBL17368421 | 0.81 | RAB9A (0.57) | MAPTSMN1; SMN2RAB9AKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2518056-B1 | SEVEN-MEMBERED RING COMPOUND AND PHARMACEUTICAL USE THEREFOR | DAIICHI SANKYO CO LTD (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-8846660-B2 | Seven-membered ring compound and pharmaceutical use therefor | DAIICHI SANKYO COMPANY, LTD. (JP) | 2014-09-30 | — | — | US | disclosed |
| EP-2518056-A1 | SEVEN-MEMBERED RING COMPOUND AND PHARMACEUTICAL USE THEREFOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-20120259111-A1 | SEVEN-MEMBERED RING COMPOUND AND PHARMACEUTICAL USE THEREFOR | DAIICHI SANKYO COMPANY LIMITED (JP) | 2012-10-11 | — | — | US | disclosed |
| EP-0530579-B1 | Condensed pyrimidine derivatives antitumor agents | EISAI CO LTD (JP) | 1998-11-11 | — | — | EP | disclosed |
| US-5688800-A | ANTITUMOR AGENTS | EISAI CO., LTD. (JP) | 1997-11-18 | — | — | US | disclosed |
| US-5554615-A | ANTITUMOR | EISAI CO., LTD. (JP) | 1996-09-10 | — | — | US | disclosed |
| EP-0215063-B1 | PYRIDO (2,3-d )PYRIMIDIN DERIVATIVES | UNIV PRINCETON (US) | 1993-11-03 | — | — | EP | disclosed |
| EP-0530579-A1 | Condensed pyrimidine derivatives antitumor agents | Eisai Co., Ltd. (JP) | 1993-03-10 | — | — | EP | disclosed |
| CN-1016174-B | Process for preparing pyrido [2.3-d ] pyrimidine derivatives | UNIV PRINCETON (US) | 1992-04-08 | — | — | CN | disclosed |
| US-5026851-A | Antineoplastic agents | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1991-06-25 | — | — | US | disclosed |
| US-4845216-A | ANTITUMOR AGENTS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1989-07-04 | — | — | US | disclosed |
| US-4684653-A | ANTITUMOR AGENTS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1987-08-04 | — | — | US | disclosed |
| CN-86101475-A | The preparation and the application of pyrido [2,3-d] pyrimidine derivatives | — | 1987-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259111-A1 | SEVEN-MEMBERED RING COMPOUND AND PHARMACEUTICAL USE THEREFOR | CMA1, CPA3, TMPRSS15 | CA12 1136/4885CA1 2390/4885CA2 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.